repotrectinib
Selected indexed studies
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. (N Engl J Med, 2024) [PMID:38197815]
- Repotrectinib. (, 2006) [PMID:38163333]
- Repotrectinib. (, 2012) [PMID:40310964]
_Worker-drafted node — pending editorial review._
Connections
repotrectinib is a side effect of
Sources
- Repotrectinib in ROS1 Fusion-Positive Non-Small-Cell Lung Cancer. (2024) pubmed
- Repotrectinib. (2006) pubmed
- Repotrectinib. (2012) pubmed
- Repotrectinib: First Approval. (2024) pubmed
- Repotrectinib (TPX-0005) Is a Next-Generation ROS1/TRK/ALK Inhibitor That Potently Inhibits ROS1/TRK/ALK Solvent- Front Mutations. (2018) pubmed
- Repotrectinib: a promising new therapy for advanced nonsmall cell lung cancer. (2024) pubmed
- Repotrectinib: Redefining the therapeutic landscape for patients with ROS1 fusion-driven non-small cell lung cancer. (2024) pubmed
- Repotrectinib effective in ROS1-fusion-positive NSCLC. (2024) pubmed
- Translational Strategies for Repotrectinib in Neuroblastoma. (2021) pubmed
- FDA Approval Summary: Repotrectinib for Locally Advanced or Metastatic ROS1-Positive Non-Small Cell Lung Cancer. (2024) pubmed